{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:33:17Z","timestamp":1781789597872,"version":"3.54.5"},"reference-count":18,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106139"],"award-info":[{"award-number":["JP16ck0106139"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ck0106351"],"award-info":[{"award-number":["JP18ck0106351"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H26\u2010144"],"award-info":[{"award-number":["H26\u2010144"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the JCOG1108\/WJOG7312G trial, a combination (FLTAX) of 5\u2010fluorouracil (FU) \/leucovorin (FL) and paclitaxel (PTX) did not show superiority in overall survival (OS) to FL in untreated patients with severe peritoneal metastasis of gastric cancer (GC\u2010SPM), some of whom received second\u2010line chemotherapy with PTX after FL. This post hoc study aimed to investigate the clinical implications of using both FU and PTX either sequentially or in combination for patients with GC\u2010SPM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 94 patients were enrolled and categorized into the following three subgroups: patients treated with (1) FL followed by PTX (FL\/PTX, <jats:italic>N\u00a0<\/jats:italic>=\u00a025), (2) FL followed by best supportive care (BSC) (FL\/BSC, <jats:italic>N<\/jats:italic>\u00a0=\u00a021), and (3) FLTAX (<jats:italic>N<\/jats:italic>\u00a0=\u00a048). OS was compared between the subgroups. By comparing baseline factors between the FL\/PTX and FL\/BSC subgroups, factors preventing the sequential use of PTX (SUP) were explored using logistic regression model. The efficacy of FL and FLTAX was compared according to the presence of risk factors preventing SUP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The FL\/PTX subgroup showed better and equivalent OS compared to the FL\/BSC (median 7.8 vs. 2.0\u00a0months, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01) and FLTAX (median 7.8 vs. 8.0, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.49) subgroups, respectively. Glasgow Prognostic Score 2 and initially unresectable disease were identified as risk factors preventing SUP. Absence of both risks predicted SUP with a sensitivity of 13% and a specificity of 100%, whereas absence of any risks predicted SUP with a sensitivity of 67% and a specificity of 62%. FLTAX showed better OS than FL in patients with one or two of these risks but worse OS in those with none.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although sequential use of FU and PTX showed equivalent survival to FLTAX in patients with GC\u2010SPM, FLTAX might be preferable given the difficulty in selecting patients likely to receive sequential use at the initiation of first\u2010line chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4303","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:07:05Z","timestamp":1634760425000},"page":"7673-7682","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108\/WJOG7312G"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-7070","authenticated-orcid":false,"given":"Hiroyuki","family":"Arai","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology St. Marianna University School of Medicine Kawasaki Japan"},{"name":"Norris Comprehensive Cancer Center University of Southern California Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Showa University Research Administration Center Showa University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saitama Cancer Center Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nishina","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Hospital Organization Shikoku Cancer Center Matsuyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Oncology Hyogo Cancer Center Akashi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East Kashiwa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology Hiroshima Prefectural Hospital Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"West Japan Oncology Group (WJOG) Data Center Division Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichinosuke","family":"Hyodo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University of Tsukuba Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-743X","authenticated-orcid":false,"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Aichi Cancer Center Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sasako","sequence":"additional","affiliation":[{"name":"Department of Surgery Yodogawa Christian Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[{"name":"Division of Gastric Surgery Shizuoka Cancer Center Nagaizumi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako E.","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology St. Marianna University School of Medicine Kawasaki Japan"},{"name":"Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki\u2010CONNECT) Kyoto University Hospital Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082654"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023795"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10740"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.154"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1561-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70259-1"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70035-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu472"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-011-0056-y"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1198-7"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5720-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01043-x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i9.1412"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.9.1485"},{"issue":"3","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s10120-015-0542-8","article-title":"Randomized phase II study of second\u2010line chemotherapy with the best available 5\u2010fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5\u2010fluorouracil\u2010containing regimens (JCOG0407)","volume":"19","author":"Nishina T","year":"2016","journal-title":"Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01802-x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2016.12.330"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4303","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:57:20Z","timestamp":1693213040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":18,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/cam4.4303"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4303","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"2021-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}